Activation of the Interferon Pathway is Dependent Upon Autoantibodies in African-American SLE Patients, but Not in European-American SLE Patients by Kichul Ko et al.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ORIGINAL RESEARCH ARTICLE
published: 01 October 2013
doi: 10.3389/fimmu.2013.00309
Activation of the interferon pathway is dependent upon
autoantibodies in African-American SLE patients, but not
in European-American SLE patients
Kichul Ko1,Yelena Koldobskaya1, Elizabeth Rosenzweig1 andTimothy B. Niewold 2*
1 Section of Rheumatology, Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago IL, USA
2 Department of Immunology, Division of Rheumatology, Mayo Clinic, Rochester, MN, USA
Edited by:
Fabrizio Mattei, Istituto Superiore di
Sanità, Italy
Reviewed by:
Dalil Hannani, Institut de Cancérologie
Gustave Roussy – INSERM U1015,
France
Kamil R. Kranc, University of
Edinburgh, UK
*Correspondence:
Timothy B. Niewold, Department of
Immunology, Division of
Rheumatology, Mayo Clinic, 200 1st
Street SW, Guggenheim Building
3-42, Rochester, MN 55905, USA
e-mail: niewold.timothy@mayo.edu
Background: In systemic lupus erythematosus (SLE), antibodies directed at RNA-binding
proteins (anti-RBP) are associated with high serum type I interferon (IFN), which plays an
important role in SLE pathogenesis. African-Americans (AA) are more likely to develop SLE,
and SLE is also more severe in this population.We hypothesized that peripheral blood gene
expression patterns would differ between AA and European-American (EA) SLE patients,
and between those with anti-RBP antibodies and those who lack these antibodies.
Methods: Whole blood RNA from 33 female SLE patients and 16 matched female con-
trols from AA and EA ancestral backgrounds was analyzed on Affymetrix Gene 1.0 ST gene
expression arrays. Ingenuity Pathway Analysis was used to compare the top differentially
expressed canonical pathways amongst the sample groups. An independent cohort of 116
SLE patients was used to replicate findings using quantitative real-time PCR (qPCR).
Results: Both AA and EA patients with positive anti-RBP antibodies showed over-
expression of similar IFN-related canonical pathways, such as IFN Signaling (P=1.3×10−7
and 6.3×10−11 in AA vs. EA respectively), Antigen Presenting Pathway (P=1.8×10−5
and 2.5×10−6), and a number of pattern recognition receptor pathways. In anti-RBP neg-
ative (RBP−) patients, EA subjects demonstrated similar IFN-related pathway activation,
whereas no IFN-related pathways were detected in RBP−AA patients. qPCR validation
confirmed similar results.
Conclusion:Our data show that IFN-induced gene expression is completely dependent on
the presence of autoantibodies in AA SLE patients but not in EA patients. This molecular
heterogeneity suggests differences in IFN-pathway activation between ancestral back-
grounds in SLE. This heterogeneity may be clinically important, as therapeutics targeting
this pathway are being developed.
Keywords: systemic lupus erythematosus, interferon alpha, autoantibodies, ancestral background, interferon
gamma
INTRODUCTION
Systemic lupus erythematosus (SLE) is a heterogeneous disease
characterized by complex genetic contributions and activation of
a number of immune system pathways (1–3). Recent advances
in human genetic studies have helped us better understand the
immunopathogenesis of the disorder (4, 5). Multiple candidate
gene association studies and genome wide association studies have
led to discovery of more than 30 susceptibility loci throughout the
whole genome, most of which are involved in three main pathways
Abbreviations: AA, African-American; ANA, antinuclear antibodies; Anti-dsDNA,
anti-double-stranded DNA; Anti-RBP, anti-RNA-binding protein; Anti-RNP, anti-
ribonucleoprotein; Anti-Sm, anti-smith; EA, European-American; HA, Hispanic-
American; IFIGs, IFN-inducible genes; IFN, interferon; IPA, ingenuity pathway
analysis; PRRs, pattern recognition receptors; qPCR, quantitative real-time PCR;
RBP+, anti-RBP antibody positive; RBP−, anti-RBP antibody negative; RLRs, RIG-
I like receptors; SLE, systemic lupus erythematosus; TLR, toll-like receptor; UCMC,
University of Chicago Medical Center.
in lupus pathogenesis: abnormal clearance of nuclear debris and
immune complexes, over-activation of innate immune system
through Toll-like receptor (TLR) and type I interferon (IFN) sig-
naling, and aberrant adaptive immune response through B and T
cell signaling (6, 7). Moreover, gene expression microarray studies
have been instrumental in defining important aspects of the com-
plex immunological pathogenesis in human subjects (8, 9). Several
gene expression analyses in SLE have found up-regulation of IFN-
inducible genes (IFIGs) in more than 50% of patients (10–13),
and others have shown differential expression of genes involved in
several pathways including inflammation, apoptosis, DNA repair,
and T cell activation (12, 14–17).
Interferon-α is a pleiotropic type I IFN which plays a key path-
ogenic role in lupus development (18). It is an anti-viral cytokine
which is regulated by endosomal pattern recognition receptors
(PRRs) such as TLRs or cytosolic PRRs like RIG-I like receptors
(RLRs) (18, 19). It has the potential to break self-tolerance by
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inducing dendritic cell differentiation which in turn leads to acti-
vation of autoreactive T and B cells, thus linking innate and
adaptive immune systems (20, 21). IFN-α is a heritable risk factor
in SLE (22, 23) and some people who have received recombinant
human IFN-α as a treatment for viral hepatitis C or malignancy
have developed de novo SLE which resolves upon discontinuation
of the IFN-α treatment (24). These data strongly support a causal
role for IFN-α in SLE pathogenesis. Increased activity of IFN-
α has been associated with presence of various SLE-associated
autoantibodies, both anti-double-stranded DNA (anti-dsDNA)
and anti-RNA-binding protein (anti-RBP) antibodies along with
different organ involvement such as hematologic, renal, and cen-
tral nervous systems (10, 25, 26). However, longitudinal studies
have not confirmed the association between increases in IFIG
expression and disease flare (27, 28). It seems that patients with
high IFN-α have more severe disease and a higher rate of flare on
average, but the changes in IFN-α levels in circulation do not cor-
relate closely or quantitatively with changes in measures of disease
activity over time.
Systemic lupus erythematosus is both more prevalent and more
severe in African-American (AA) populations than in European-
American (EA) populations, and disease manifestations are vari-
able amongst different ancestral backgrounds (29–32). AA and
Hispanic-American (HA) patients are likely to have more active
SLE, with an earlier age at onset, than EA patients (31, 32). Anti-
ribonucleoprotein (anti-RNP) and anti-Smith (anti-Sm) antibod-
ies are more prevalent in AA patients than in EA and HA (30,
32), and a number of genetic variants are associated with autoan-
tibody profiles in different ancestral groups (33, 34). Moreover,
compared to EA patients, HA, and AA patients have a higher inci-
dence of SLE-related renal disease, associated with anti-dsDNA
and anti-RNP antibodies (31,35). Additionally, some of the genetic
factors associated with SLE are not shared between AA and EA
patients (36–39). These data all support the idea that molecular
and biological differences should exist in SLE patients of different
ancestral backgrounds. We have shown that overall serum IFN-α
activity is higher in SLE patients of non-European ancestry as com-
pared to European ancestry, either directly or indirectly through
an increased prevalence of anti-RBP antibodies (40, 41). In this
study, we compare peripheral blood gene expression between AA
and EA SLE patients taking into account the differences in autoan-
tibody profile, and we find a striking difference in the activation
of the IFN pathway between the two groups.
MATERIALS AND METHODS
PATIENTS, SAMPLES, AND DATA COLLECTION
Serum samples were obtained from 149 female SLE patients from
the University of Chicago Medical Center (UCMC) (n= 119) and
NorthShore University Health System (n= 30). All cases fulfilled
the American College of Rheumatology criteria for the diagnosis of
SLE (1, 42), and the data regarding the presence or absence of these
criteria as well as of SLE-associated autoantibodies [anti-nuclear
antibodies (ANA), and anti-Ro, anti-La, anti-Sm, anti-RNP, and
anti-dsDNA antibodies] were available for all patients. Forty-nine
unrelated females who were screened by medical record review
for the absence of autoimmune disease were used as controls.
They were of similar age (P = 0.21) as the SLE cases. All subjects
provided informed consent, and the study was approved by the
institutional review boards at the Mayo Clinic and University of
Chicago.
DETECTION OF AUTOANTIBODIES
Antibodies to Ro, La, Sm, and RNP for all samples were measured
by ELISA methods (INOVA Diagnostics, San Diego, CA, USA) at
UCMC at the time of serum and RNA sampling, and standard
clinical laboratory cutoff points were used to categorize them as
positive or negative. Anti-dsDNA antibodies were measured using
Crithidia luciliae immunofluorescence at UCMC, and detectable
fluorescence was considered positive.
GENE EXPRESSION ANALYSIS
Thirty-three SLE cases and 16 age-matched controls were selected
for microarray gene expression analysis. The cases were subdivided
into AA and EA patients, and those with positive anti-RBP anti-
bodies and those without as described in Table 1. Whole blood
from the subjects was collected in PAX gene tubes (Qiagen), and
RNA was purified in spin columns per manufacture recommen-
dations. The RNA was analyzed on Affymetrix Gene 1.0 ST gene
expression arrays, which were run in the University of Chicago
Microarray Core facility. These intensity data were normalized
through Affymetrix Expression Console software. Data from the
microarray experiment have been deposited in the GEO database,
accession number GSE50635.
Quantitative real-time PCR (qPCR) was used to validate the
hypotheses generated from the microarray data with an indepen-
dent replication cohort. The RNA of whole blood from 60 AA SLE
patients, 47 anti-RBP antibody positive (RBP+), and 13 anti-RBP
antibody negative (RBP−), and 56 EA SLE patients, 21 RBP+ and
24 RBP− along with 25 AA and 8 EA controls was purified using
Qiagen RNeasy kit. cDNA was synthesized from total mRNA, and
qPCR was used to measure relative transcript expression using
SYBR Green dye on an ABI 7900HT thermal cycler.
STATISTICAL ANALYSIS
For each ancestry, the anti-RBP antibody status was used as
a dichotomous variable, and each subgroup was compared to
respective controls from the same ancestral background. Following
normalization, the mean microarray gene expression values along
Table 1 | Samples and data collection for microarray analysis*.
SLE cases** Non-autoimmune
controls
RBP+ RBP−
European-American Female 8 8 8
African-American Female 9 8 8
*There was no difference in age amongst the groups.
**All SLE cases fulfilled the ACR criteria for SLE. Anti-RBP (anti-Ro, anti-La, anti-
Sm, and anti-RNP) antibodies were measured by ELISA, and anti-dsDNA antibody
levels were measured using Crithidia luciliae immunofluorescence.
RBP+, anti-RNA-binding-protein (RBP) antibody positive; RBP−, RBP antibody
negative.
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with standard deviations were calculated for each subgroup and
used to calculate the fold changes between subjects and controls.
Values were compared between the groups using the two-tailed
Student’s unpaired t -test. Similar comparisons were made with
the qPCR data, but this time, all group results were expressed in
medians and compared using Mann–Whitney tests as they did
not follow Gaussian distributions. For both microarray and qPCR
analyses, P values less than 0.05 were considered significant.
CANONICAL PATHWAY ANALYSIS
From the microarray data, the differentially expressed genes with
a cutoff P value of 0.05 along with their respective fold changes
were analyzed further through Ingenuity Pathway Analysis (IPA)
(Ingenuity® Systems, www.ingenuity.com) to compare the top
canonical pathways amongst the sample groups (Table 1). The
IPA canonical pathway analysis identified the pathways from the
IPA Knowledge Base that were most significant to the data set. The
significance of the association between the data set and the canon-
ical pathway was measured in two ways: (1) A ratio of the number
of molecules from the data set that map to the pathway divided by
the total number of molecules that map to the canonical pathway
was displayed. (2) Fisher’s exact test was used to calculate a P value
determining the probability that the association between the genes
in the dataset and the canonical pathway was explained by chance
alone.
RESULTS
DEMOGRAPHICS AND PRESENCE OF ANA AND ANTI-dsDNA
ANTIBODIES
The average age of all subjects included in the microarray portion
of the study was 43.5± 10.6 years. When the subjects and con-
trols were divided into subgroups according to ancestry and the
presence of anti-RBP antibodies (Table 1), there was no statis-
tical difference in age amongst the subgroups including controls.
There was lower prevalence in anti-dsDNA antibodies in RBP−AA
patients (77% of RBP+ vs. 31% of RBP− had anti-dsDNA anti-
bodies, P = 0.005). In EA subjects, this difference was much less
pronounced, and was not statistically significant (66% of RBP+
vs. 54% of RBP− had anti-dsDNA antibodies, P = 0.4). This is
in concordance with our previous large-scale analyses in SLE, in
which we have also found that anti-RBP and anti-dsDNA anti-
bodies are more correlated in AA as compared to EA SLE patients
(40). All subjects were female and all tested positive for ANA.
IFN-RELATED CANONICAL PATHWAY ACTIVATION IN AA vs. EA SLE
PATIENTS
Top 10 canonical pathways from each subgroup are shown in
Table 2. Many immune system associated pathways were asso-
ciated with the cases, and similar to previous studies, type I
IFN-related pathways were the most differentially expressed when
comparing cases vs. controls except in RBP−AA group. We exam-
ined in greater detail the six canonical pathways which were type I
IFN-related across patients from the two different ancestral back-
grounds studied. As shown in Table 3, the microarray analysis of
all SLE cases vs. controls demonstrated all six IFN-related canon-
ical pathways significantly involved. The same pattern was also
observed for all EA cases vs. controls. However, to our surprise,
the associations between the IFN-related canonical pathways and
AA SLE cases were not as strong as only three out of six path-
ways were found to be significant. This is despite that fact that
high circulating levels of type I IFN are more common in AA SLE
patients (40).
IFN-RELATED CANONICAL PATHWAY ACTIVATION IS NOT SEEN IN
RBP− AA PATIENTS
To explore this further, we looked at the associations between IFN-
related canonical pathways within SLE patient subgroups stratified
by both ancestry and the presence or absence of anti-RBP antibod-
ies. As shown in Table 4, all six type I IFN-related pathways were
activated in both AA and EA RBP+ patients. The key pathway dif-
ference was found between AA and EA patients who were RBP−.
RBP− EA patients demonstrated activation of all six IFN-related
canonical pathways, whereas not a single type I IFN pathway was
significantly involved in the RBP− AA patients.
IFN-INDUCED GENE EXPRESSION PATHWAY DIAGRAMS IN AA vs. EA
PATIENTS
In Figure 1, we show pathway diagrams generated in IPA software
of the type I and type II IFN pathways, with genes that were up-
regulated in cases vs. controls shaded red. It is striking that none
of the genes illustrated downstream of the type I and type II IFN
receptors are up-regulated in the RBP− AA patients, while in the
RBP− EA patients, many IFN-induced genes are over-expressed.
It is also interesting that STAT1 over-expression is observed in the
RBP+ subjects regardless of ancestral background, and this is not
observed in the RBP− patients from either ancestral background.
REPLICATION STUDY CONFIRMS THE DEPENDENCE OF IFN-INDUCED
GENE EXPRESSION UPON PRESENCE OF ANTI-RBP ANTIBODIES IN AA
PATIENTS, BUT NOT EA PATIENTS
Three IFIGs (IFIT1, MX1, and PKR) were selected for qPCR analy-
sis to replicate the microarray observation with regards to the
association between anti-RBP antibodies and IFN-related gene
expression across different ancestral backgrounds. These genes
were quantified in whole blood mRNA from an independent
cohort of 116 SLE patients and 33 controls. As shown in Figure 2,
the pattern observed mirrors the microarray data. All three genes
were up-regulated in both EA and AA RBP+ patients. In the
RBP−patients, there is essentially no increase in IFN-induced gene
expression in AA patients, while the expression of these genes, in
particular PKR, is increased in the RBP− EA SLE patients. Because
anti-dsDNA antibodies have been associated with high IFN-α (25,
26), it is important to determine whether anti-dsDNA antibodies
are contributing to the induction of IFN-induced gene expres-
sion we observe in our RBP− EA patients. As noted above, the
RBP−EA subjects were more likely to have anti-dsDNA antibodies
than the RBP− AA subjects. When we looked at the RBP negative
patients in the qPCR replication cohorts with regard to presence
or absence of anti-dsDNA antibodies, there was no significant dif-
ference in IFIT1, MX1, or PKR over-expression in the AA subjects.
In RBP− EA patients, however, over-expression of IFN-induced
genes (IFIT1 and PKR) was observed in the anti-dsDNA antibody
positive patients but not in the anti-dsDNA antibody negative
group (Figure 3). Thus, in RBP− EA subjects, the anti-dsDNA
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Table 2 |Top 10 canonical pathways from each subgroup vs. matching controls through IPA from microarray data.
All cases All EA All AA EA RBP+ EA RBP− AA RBP+ AA RBP−
EIF2 signaling Interferon signaling EIF2 signaling Interferon
signaling
Antigen
presentation
pathway
EIF2 signaling Regulation of IL-2
expression in
activated and
anergic T
lymphocytes
Interferon signaling Antigen presentation
pathway
Activation of IRF
by cytosolic
pattern
recognition
receptors
Activation of IRF
by cytosolic
pattern
recognition
receptors
OX40 signaling
pathway
Regulation of
eIF4 and p70S6K
signaling
Glucocorticoid
receptor signaling
Antigen presentation
pathway
Role of pattern
recognition
receptors in
recognition of
bacteria and viruses
Angiopoietin
signaling
Antigen
presentation
pathway
Autoimmune
thyroid disease
signaling
mTOR signaling CD28 signaling in
T helper cells
Activation of IRF by
cytosolic pattern
recognition
receptors
Retinoic acid
mediated apoptosis
signaling
Regulation of
eIF4 and p70S6K
signaling
Role of pattern
recognition
receptors in
recognition of
bacteria and
viruses
Allograft rejection
signaling
Activation of IRF
by cytosolic
pattern
recognition
receptors
T cell receptor
signaling
IL-12 signaling and
production in
macrophages
Activation of IRF by
cytosolic pattern
recognition
receptors
Hypoxia signaling
in the
cardiovascular
system
IL-15 production Interferon
signaling
Interferon
signaling
Glycosphingolipid
biosynthesis -
globoseries
mTOR signaling Graft-vs.-host
disease signaling
Role of RIG1-like
receptors in
antiviral innate
immunity
Retinoic acid
mediated
apoptosis
signaling
Graft-vs.-host
disease signaling
Apoptosis
signaling
Biosynthesis of
steroids
Role of pattern
recognition
receptors in
recognition of
bacteria and viruses
Dendritic cell
maturation
mTOR signaling Role of RIG1-like
receptors in
antiviral innate
immunity
Cytotoxic T
lymphocyte-
mediated
apoptosis of
target cells
Colorectal cancer
metastasis
signaling
April mediated
signaling
TNFR2 signaling IL-15 production Hereditary breast
cancer signaling
Communication
between innate
and adaptive
immune cells
Crosstalk
between
dendritic cells and
natural killer cells
TNFR2 signaling Reelin signaling in
neurons
Production of nitric
oxide and reactive
oxygen species in
macrophages
Autoimmune thyroid
disease signaling
Role of PI3K/AKT
signaling in the
pathogenesis of
influenza
Dendritic Cell
maturation
Type I diabetes
mellitus signaling
IL-8 signaling Glycosphingolipid
biosynthesis –
neolactoseries
IL-15 production Communication
between innate and
adaptive immune
cells
TNFR2 signaling Starch and
sucrose
metabolism
Dendritic cell
maturation
P2Y purigenic
receptor signaling
pathway
Mitotic roles of
polo-like kinase
IPA, ingenuity pathway analysis; EA, European-American; AA, African-American; RBP+, anti-RNA-binding-protein (RBP) antibody positive; RBP−, RBP antibody neg-
ative; eIF2, eukaryotic initiation factor 2; IRF, interferon-regulatory factor; mTOR, mammalian target of rapamycin; TNFR2, tumor necrosis factor receptor 2; eIF4,
eukaryotic initiation factor 4; RIG1, retinoic acid-inducible gene 1; PI3K, phosphatidylinositol 3-kinase; OX40=CD134.
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Table 3 | P values for IPA IFN-related canonical pathways from microarray data.
All SLE cases
(n=33)
EA SLE cases
(n=16)
AA SLE cases
(n=17)
Interferon signaling 1.53×10−10 6.55×10−12 0.29
Activation of IRF by cytosolic pattern recognition receptors 6.14×10−5 2.74×10−5 8.46×10−5
Role of RIG1-like receptors in antiviral innate immunity 1.63×10−4 5.85×10−7 0.044
Role of PKR in interferon induction and antiviral response 0.020 0.038 0.091
Role of pattern recognition receptors in recognition of bacteria and viruses 0.0097 0.0064 0.0011
Communication between innate and adaptive immune cells 0.0098 0.0013 Not listed
IPA, ingenuity pathway analysis; IFN, interferon; SLE, systemic lupus erythematosus; EA, European-American; AA, African-American; IRF, interferon-regulatory factor;
RIG1, retinoic acid-inducible gene 1; and PKR, protein kinase R.
Table 4 | P values from IPA IFN-related canonical pathways from microarray data.
EA RBP+ EA RBP− AA RBP+ AA RBP−
Interferon signaling 5.8×10−11 10.6×10−5 1.3×10−7 0.063
Activation of IRF by cytosolic pattern recognition receptors 1.1×10−6 0.016 2.86×10−8 0.25
Role of RIG1-like receptors in antiviral innate immunity 2.0×10−5 0.030 0.0014 Not listed
Role of PKR in interferon induction and antiviral response 0.0073 0.042 9.0×10−4 Not listed
Role of pattern recognition receptors in recognition of bacteria and viruses 1.8×10−4 0.028 5.8×10−4 0.31
Communication between innate and adaptive immune cells 0.0043 0.0064 0.023 Not listed
IPA, ingenuity pathway analysis; IFN, interferon; EA, European–American; AA, African-American; RBP+, anti-RNA-binding-protein (RBP) antibody positive; RBP−, RBP
antibody negative; IRF, interferon-regulatory factor; RIG1, retinoic acid-inducible gene 1; and PKR, protein kinase R.
antibody status did have an effect on expression of IFIGs, and thus
anti-dsDNA antibodies are contributing to the IFN-induced gene
expression in this group. Strikingly, anti-dsDNA antibodies had
no impact upon IFN-induced gene expression in the RBP− AA
group. This was somewhat unexpected and reinforces the idea of
RBP antibody dependence in the AA ancestral background.
DISCUSSION
To our knowledge, this was the first study to show differential gene
expression patterns in various subgroups of SLE patients strati-
fied by ancestral background and presence or absence of anti-RBP
antibodies. Through microarray whole genome expression with
pathway analysis followed by independent qPCR validation, we
demonstrated that activation of IFN-related pathways depended
on presence of anti-RBP antibodies in AA patients, but not in EA
patients. The results also support the model suggested by our pre-
vious study in which African ancestry increases the likelihood of
SLE-associated autoantibody formation, leading to higher IFN-α
activity (41). In the present study, we observe a similar dependence
of IFN-induced gene expression upon anti-RBP antibodies in AA
patients, and this is not shared with the EA patients, and this novel
observation should be confirmed in larger cohorts.
Autoantibody immune complexes present in SLE patients have
been implicated as major endogenous IFN-inducers, likely via the
endosomal TLR and IFN regulatory factor pathways (43–45). Our
data would suggest that the classical activation of IFN-related path-
ways observed in SLE patients is highly dependent upon anti-RBP
antibodies in AA SLE patients, and this dependence is not shared by
EA SLE patients. The additional IFN-pathway activation observed
in EA subjects is partly due to the presence of anti-dsDNA anti-
bodies. As shown in Figure 3 there are a number of anti-dsDNA
and anti-RBP negative EA patients that show over-expression of
IFN-induced genes, while in AA SLE patients lacking RBP anti-
bodies, IFN-induced gene expression resembles the AA control
population. This heterogeneity in the dependence of IFN-related
pathways on autoantibody profile may reflect differential activa-
tion of the TLR pathway is SLE patients of different ancestral
backgrounds. Anti-RBP antibodies would be expected to activate
the RNA-sensing TLRs, while anti-dsDNA antibody immune com-
plexes would be expected to activate TLR 9. Genetic variations in
the TLR pathway genes such as IRF5 and IRF7 have been associated
with risk of SLE, and with gain of function within the type I IFN
pathway (46, 47). In our previous study looking at genetic varia-
tion at the IRF7/PHRF1 locus, we observed two different high IFN
genetic effects in AA subjects, while we saw only one in EA sub-
jects (46). This example demonstrates genetic diversity between
world populations in the TLR/IRF system, and could support the
idea that this pathway may more prominent in AA subjects and
help to explain the findings we report here. Additionally, many of
the genetic polymorphisms we have discovered that are associated
with increased type I IFN in SLE patients differ between ancestral
backgrounds (34, 48), and this would also support the idea that
the pathway will be more or less prominent in different ancestral
backgrounds.
There were EA SLE patients that had increased expression
of IFN-induced genes who did not have either anti-RBP or
anti-dsDNA autoantibodies. These data suggest that IFN-related
pathways may be activated through different mechanisms in this
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FIGURE 1 | Pathway diagram illustrating the type I and type II IFN
pathways in SLE patient subsets. Genes which are up-regulated are
shaded red, with increasingly dark red shading indicating a greater
degree of over-expression in cases as compared to controls of the same
ancestral background. AA, African-American; EA, European-American;
RBP+, anti-RNA-binding-protein (RBP) antibody positive; and RBP−, RBP
antibody negative. Pictures generated using Ingenuity Pathway Analysis
software.
ancestral background. All patients in our study had ANA, and it
may be that other nuclear antigen/autoantibody complexes could
have triggered the TLR/RLR system leading to IFN-pathway acti-
vation in these subjects. It is also possible that other molecules
such as HMGB1, which can bind with immune complexes, may
be activating an inflammatory cascade in plasmacytoid dendritic
cells resulting in activation of IFN pathways (49). Another possi-
bility is that there is an increased sensitivity to IFN signaling or
a downstream activator of IFN-induced gene expression in these
patients. We have observed some SLE patients in previous stud-
ies that have high IFN-induced gene activity in their PBMC with
essentially normal circulating type I IFN activity from the same
sample (50, 51).
This surprising diversity in IFN-pathway activation between
different SLE patient subgroups is relevant to clinical care, as ther-
apeutics directed at IFN or IFN-related pathways are being actively
developed (52). It seems likely that these IFN-pathway targeting
therapeutics will be characterized by heterogeneity in treatment
response, and our results may suggest some groups that are likely
to be better responders that could be predicted without having to
run a gene expression chip prior to therapy. The RBP− AA group
is very interesting in this regard, as it seems that this patient group
may represent a distinct subset of SLE patients which is not as
IFN-dependent as other groups of SLE patients. This may repre-
sent a significant difference in disease pathogenesis, which could
be important in planning targeted therapies.
CONCLUSION
Systemic lupus erythematosus is a heterogeneous disease with
differences in disease incidence, clinical manifestations, serolog-
ical findings, and genetic risk factors between ancestral back-
grounds (7, 29–32, 36–39). Perhaps it is not very surprising
to find heterogeneity in the activation of molecular pathways
between ancestral groups, and it seems likely that different
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FIGURE 2 |Type I IFN-induced gene expression in SLE patient subgroups
and controls. Expression of three genes (IFIT1, MX1, and PKR) are shown in
both patients with anti-RNA-binding protein antibodies (RBP+), and those
who lack those antibodies (RBP−). Central tendency shown is a median, with
error bars representing the interquartile range. P values generated by
Mann–Whitney U test.
FIGURE 3 |Type I IFN-induced gene expression in RBP−SLE patient
subgroups and controls in regards to of anti-dsDNA antibodies.
Expression of three genes (IFIT1, MX1, and PKR) are shown in both patients
with anti-dsDNA antibodies (DNA+), and those who lack those antibodies
(DNA−). Central tendency shown is a median, with error bars representing
the interquartile range. P values generated by Mann–Whitney U test.
pathogenic factors will be relevant in RBP− AA patients as
compared to the RBP+ SLE patients. SLE is a complex autoim-
mune disease, and understanding heterogeneity in the molecular
pathogenesis in lupus will be crucial in informing therapeu-
tic and diagnostic strategies. This study demonstrates the rele-
vance of careful patient characterization and including patients
from more than one ancestral background in biological studies
of SLE.
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